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Introduction
Carcinomatous meningitis is a debilitating and progressive
complication of cancer that results from metastatic infil-
tration of the leptomeninges and the cerebrospinal fluid
(CSF) by cancer cells. Among all solid tumors, breast
and lung cancers, melanoma, and gastrointestinal tract
cancer most frequently metastasise to the leptomeninges
[1, 2]. Carcinomatous meningitis occurs in 1 to 5% of
patients with breast cancer [1, 2]. The growing incidence
of neoplastic meningitis is thought to be due both to the
longer survival of cancer patients seen with current sys-
temic therapies and to enhanced clinical vigilance and
improved diagnostic tests [3].
The most common symptoms include headache,
changes in mental status, cranial nerve palsies, back or
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I n t r o d u c t i o n.  Carcinomatous meningitis is an uncommon but serious complication of advanced breast cancer, the
incidence of which has been, recently, increasing.
M a t e r i a l  a n d  m e t h o d s.  We have reviewed 25 cases of carcinomatous meningitis in breast cancer patients treated in our
clinic. The mean age at the time of diagnosis was 45 years (range: 29-70 years). The clinical symptoms at the time of diagnosis
were headache, nausea/vomiting, confusion, cerebellar signs, paresis and pain in the thoraco-lumbal region. Cancer cells in
cerebrospinal fluid were detected in all the cases. Cerebrospinal fluid protein level was elevated in 72% of cases. The treatment
consisted of intrathecal injection of 10 mg of methotrexate plus dexamethasone 4 mg, administered weekly. 
R e s u l t s.  The response defined as clinical and laboratory improvement was achieved in 72% of patients.
C o n c l u s i o n.  Our observations suggest that the important prognostic factors in carcinomatous meningitis are: systemic
chemotherapy, Karnofsky status at the time leptomeningeal metastases of diagnosis and the clinical response after the first 2
cycles of inthratecal infusion of methotrexate.
Analiza objawów klinicznych i czynników prognostycznych w nowotworowym zapaleniu 
opon mózgowo-rdzeniowych u chorych na raka piersi
W p r o w a d z e n i e. W ostatnim czasie obserwuje si´ wyraêny wzrost iloÊci wyst´powania nowotworowego zaj´cia opon mó-
zgowo-rdzeniowych wÊród chorych na raka piersi. Rokowanie u pacjentek z tà lokalizacjà zmian przerzutowych jest bardzo z∏e.
M a t e r i a ∏  i  m e t o d y.  W naszej pracy przeanalizowaliÊmy 25 przypadków pacjentek z nowotworowym zaj´ciem opon mó-
zgowo-rdzeniowych. Ârednia wieku wynosi∏a 45 lat (od 29 do 70). Objawy kliniczne, które wyst´powa∏y w momencie rozpo-
znania, to: bóle g∏owy, nudnoÊci i wymioty, splàtanie, zespó∏ mó˝d˝kowy, niedow∏ady, bóle w okolicy piersiowo-l´dêwiowej.
W 100% przypadków potwierdzono rozpoznanie poprzez stwierdzenie obecnoÊci komórek nowotworowych w badaniu cyto-
logicznym p∏ynu mózgowo-rdzeniowego. U 72% pacjentek obserwowano tak˝e podwy˝szony poziom bia∏ka. Leczenie sk∏ada-
∏o si´ z dokana∏owo podawanego raz w tygodniu metotreksatu – 10 mg i Dx – 4 mg. 
W y n i k i.  Klinicznà odpowiedê na leczenie oraz popraw´ parametrów laboratoryjnych stwierdziliÊmy u oko∏o 72% pacjentek.
Po d s u m o w a n i e.  Nasze obserwacje wskazujà, ˝e najwa˝niejszymi korzystnymi czynnikami rokowniczymi w przerzutach do
opon mózgowo-rdzeniowych u chorych z rakiem piersi sà: jednoczasowe leczenie systemowe, dobry stan ogólny chorych
w momencie rozpoznania, dobra odpowiedê kliniczna na leczenie metotreksatem, stwierdzona po 2 cyklach leczenia.
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radicular pain, incontinence, lower motor neuron weak-
ness and sensory abnormalities. By the time most patients
are diagnosed, they have a combination of cranial nerve,
cerebral, and spinal signs and symptoms [4].
Diagnosis of carcinomatous meningitis is based on
the recognition of a combination of neurologic symptoms
and signs, plus on the demonstration of tumor cells by
cytology in the CSF [2, 3]. CSF pleocytosis and eleva-
tions in CSF protein are non-specific abnormalities that
are consistent with, but not diagnostic of, carcinomatous
meningitis. Significant reduction in CSF glucose is found
only in malignant or infectious disorders of the lep-
tomeninges [5].
Neuroimaging techniques including cranial and
spinal computed tomography or contrast-enhanced mag-
netic resonance (MR) may therefore be needed, and
a high index of suspicion may be required for prompt
diagnosis [6].
Therapy for carcinomatous meningitis has evolved to
include radiation therapy to symptomatic sites and to
regions of bulk disease in combination with intrathecal
chemotherapy. In breast cancer-related meningeal metas-
tases methotrexate is the commonly used intrathecal
agent [2-5].
The median survival of patients with carcinomatous
meningitis without therapy is approximately 4 to 6 weeks
[3]. With intratecal methotrexate and radiotherapy medi-
an survival is less than 6 months [3].
We have performed a retrospective analysis of
patients treated in our clinic to derive prognostic factors
for the better treatment of future patients.
Material and methods
We reviewed 25 consecutive cases of carcinomatous meningitis
caused by breast cancer. The neurological symptoms, pre-treat-
ment characteristics, i.e. clinical stage at breast cancer diagnosis,
tumor characteristics, receptor status, sites of metastatic lesions,
and the methods of carcinomatous meningitis treatment were
analysed. Moreover, laboratory parameters such as the CSF
exam were analysed, i.e. pleocytosis, protein and glucose lev-
els.
Concentrations analysis as a statistical test for small groups
was applied for the statistics.
The therapy of neoplastic meningitis includes radiation
therapy to symptomatic sites and regions of bulky disease, com-
bined with methotrexate intrathecal-therapy and concurrent
treatment of the breast cancer with systemic chemo- or hor-
mono- therapy. The intrathecal treatment consisted of injec-
tion of preservative-free methotrexate 10 mg, plus dexametha-
sone 4 mg, administered two or three times twice a week and,
subsequently, weekly to a maximum of twelve doses, or until
the CSF clears. The CSF exam was performed every week. Intra-
CSF chemotherapy was typically administered using the lum-
bar puncture [7].
The clinical and laboratory response to the first two doses
of intrathecal methotrexate injection was also analysed as a prog-
nostic factor.
The evaluation of responses was based on Grossman clas-
sification [8]. If progression in CSF exam, imaging studies or
clinical examination was observed, progression of the disease
was recognised.
Results
Pa t i e n t s  C h a r a c t e r i s t i c s
Twenty-five women with carcinomatous meningitis were
treated in our clinic between January 2000 and October
2001. The patients’ characteristics are presented in
Table I.
Table I. Patients characteristics
Number of patients 25
Age – mean / range 45 / 29–70
Karnofsky (%) – mean / range 50 / 40-80
Prior radical breast cancer treatment 15 (60%)
Median of the interval from breast cancer diagnosis 26 months
(from 1/2 to 84)
Prior systemic treatment of the metastatic 
breast cancer 17 (68%)
Presence of metastatic lesions in another 
localization 19 (76%)
Hormonal receptors: + / – / unknown 2 (8%) / 14 / 9
Cancer cells in cerebrospinal fluid exam 100%
The mean age at the time of diagnosis of carcino-
matous meningitis was 46 years (range 29-70) and the
median Karnofsky status was 50% (range 40-80%).
Five patients out of the 6 with Karnofsky status of 70
or 80% survived more than 6 months, while only 3
patients out of the 19 with Karnofsky of 40-60% achieved
similar survival. Median overall survival for these two
groups was 15,8 and 8,6 weeks, respectively.
The mean time from breast cancer diagnosis was 26
months (range from 1/2 to 84 months). Fourteen patients
were hormonal receptors (HR) negative (56%), in 9 cases
the hormonal status was unknown (36%). Only 2 patients
were HR positive (8%).
In 15 cases (60%) previous radical treatment of
breast cancer was performed. Seventeen (68%) women
were previously treated with systemic chemotherapy as
metastatic setting.
Other metastatic sites were associated with carcino-
matous meningitis in 19 (76%) patients.
In one case the diagnosis of carcinomatous menin-
gitis was established in pregnancy (28 weeks of gesta-
tion).
Clinical signs and symptoms of carcinomatous
meningitis are presented in Table II. In most of the cases
several symptoms were observed.
Table II. Clinical signs and symptoms
Symptoms % of patients
Headache 85%




Pain of the thoraco-lumbal region 10%
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Cancer cells in cerebrospinal fluid were detected in
100% of cases. Abnormal pleocytosis (normal range: 8
cells in field of vision) in CSF was detected in 24 patients
(96%) in initial lumbar puncture. Increase of pleocytosis
in consecutive lumbar punctions was evidence of disease
progresion and was strictly related to clinical status dete-
rioration. (Figure 1) Cerebrospinal fluid protein (normal
level: 45mg%) level was elevated in 18 cases (72%)
(Figure 2). Decreased glucose level (normal level: 1/2 of
serum level) in CSF at the time of diagnosis was observed
in almost 90% of patients (22 cases) (Figure 3).
Tr e a t m e n t  c h a r a c t e r i s t i c s
The inthratecal therapy was performed in 24 patients
(96%); 1 woman withdrew consent. The mean number
of intrathecal treatment cycles was 6, (range 0-15 cycles).
The treatment was terminated if progression of the dis-
ease was documented and these patients received pallia-
tive care. In the pregnant woman the intrathecal injections
of methotrexate and systemic chemotherapy were inter-
rupted for 5 weeks during the labour period. Eighteen
patients (72%) received systemic chemotherapy together
with intrathecal treatment and 2 patients (8%) – systemic
hormonal treatment. Individual programmes of systemic
treatment were used, because most of the patients
received one or two chemotherapies as adjuvant or
metastatic setting. In 4 cases a taxans-based program was
given, 3 patients received antracyclines. In other cases
vinorelbine with 5-fluorouracil or cisplatin in monother-
apy were used. One premenopausal patient received
goserelin with systemic chemotherapy, while in another
letrozol was used as systemic treatment. In 3 patients sys-
temic treatment was not planned because of extremely
poor clinical status and 2 other patients died before the
onset of systemic treatment. Longer median overall sur-
vival was documented for patients who had received sys-
temic therapy (18,7 vs 6,6 weeks). The whole brain radio-
therapy (2000-3000 cGy/g in 5 or 10 fractions) was per-
formed additionally in sixteen (64%) patients.
To x i c i t y
Treatment-related toxicities can occur from administra-
tion of intrathecal and systemic chemotherapy and
radiation to symptomatic areas of the central nervous
system. The most significant toxicity associated with the
treatment of carcinomatous meningitis is the development
of dementia due to necrotizing leukoencephalopathy. We
observed progressive dementia in three patients (12%),
probably as a complication of treatment. Intrathecal
methotrexate with systemic chemotherapy can cause
mucositis and myelosupression. In our observation grade
3 or 4 neutropenia occurred only in 3 patients (12%). In 6
patients (24%) grade 3 mucositis was documented.
Thrombocytopenia or anaemia were not observed.
Infectious complications of the lumbar puncture were
not documented.
Re s p o n s e  a n d  s u r v i v a l
The response was achieved in 18 patients (72%). In this
group the reduction of clinical signs of carcinomatous
meningitis i.e. headache, nausea/vomiting, confusion and
other symptoms after 2-4 cycles of intrathecal treatment
was observed. In 7 patients (28%) disease progression
occurred during the treatment. The median overall sur-
vival was 16,2 weeks. Nine patients (36%) survived
beyond 6 months (only those who received systemic
chemotherapy). One patient survived 54 weeks.
Discussion
Meningeal metastases are an uncommon, but serious,
complication of advanced breast cancer. Prognosis in this
localisation of the disease is extremely poor. Current
treatment of carcinomatous meningitis offers palliation
for many patients.
The median overall survival in our data was 16,2
weeks. Other authors have demonstrated similar results,
i.e. 10-16 weeks [1, 3, 5, 9]. The toxicity of inthratecal
treatment, particularly with radiotherapy, was high.
The most common toxicity is necrotizing leukoencephalo-
pathy. In our group in 12% of patients progressive
dementia was observed, as is reported by other authors
(9-17%) [3-5, 10].
Grossman [8] and Jayson [5] have shown that
Karnofsky status is a very important prognostic factor in
carcinomatous meningitis. Patients with Karnofsky sta-
tus of 50 or below survived for about 8 weeks, and
patients with Karnofsky status of 60 or more survived for
20-30 weeks. Our results have confirmed this observa-
tion.
Additionally, our observations suggest that systemic
chemotherapy ia also an important prognostic factor in
carcinomatous meningitis.
In historical data systemic chemotherapy was not
used in patients with carcinomatous meningitis [5, 8, 11],
and this factor was not analysed. Our data suggests that
the blood-brain barrier is disrupted when carcinomatous
meningitis develops and systemic chemotherapy can be
effective against meningeal metastases from chemosen-
sitive breast cancer.
A majority of authors [2, 3, 5, 8] emphasise that clin-
ical response (reduction of headache and other symp-
toms) after 2 weeks of the treatment is a very important
prognostic factor. In our data the clinical response after
the first 2-3 cycles of inthratecal infusion of methotrexate
was also found to be an important prognostic factor.
Our observations suggest that the important prog-
nostics factors in carcinomatous meningitis are: systemic
chemotherapy, Karnofsky status at the time of carcino-
matous meningitis diagnosis and clinical response after
the first 2 cycles of inthratecal infusion of methotrexate.
In conclusion, progress in the treatment of neoplas-
tic meningitis is rather slow. The analysis of prognostic
factors shows that systemic treatment with new active
neoplastic agents may improve the results of treatment of
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patients with breast cancer-related carcinomatous menin-
gitis.
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